Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629308 | 0.98 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2LMNATSHRTHRB | |
| SCHEMBL20183354 | 0.86 | CTSG (0.49) | ALDH1A1SMN1; SMN2LMNATSHRTHRB | |
| SCHEMBL10250933 | 0.86 | PKM (0.56) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24317428 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL29532805 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL20183381 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2LMNATSHRTHRB | |
| SCHEMBL8220526 | 0.84 | AKR1C3 (0.50) | ALDH1A1SMN1; SMN2LMNATSHRTHRB | |
| SCHEMBL15014519 | 0.82 | ALDH1A1 (0.63) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL24571620 | 0.82 | JAK2 (0.51) | ALDH1A1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL2961172 | 0.81 | HTT (0.61) | ALDH1A1SMN1; SMN2LMNATHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137608-A | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2018-06-08 | — | — | CN | claimed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| CN-108137608-A | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2018-06-08 | — | — | CN | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| CN-107001283-A | Flt3 receptor antagonists | 国家健康与医学研究院 | 2017-08-01 | — | — | CN | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
| EP-2144890-A1 | METHOD FOR PREPARING HALOGENATED AMINES | Wyeth (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008098103-A1 | METHOD FOR PREPARING HALOGENATED AMINES | WYETH (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | ALDH1A1 2419/4885SMN1; SMN2 3517/4885LMNA 4733/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | ALDH1A1 2419/4885SMN1; SMN2 3517/4885LMNA 4733/4885 |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | PNMT, ABL1, INMT | ALDH1A1 1194/4885SMN1; SMN2 3833/4885LMNA 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.